Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ANP32AP1 is classified as a pseudogene. Pseudogenes are defunct genomic sequences similar to known genes but lack protein-coding potential. ANP32AP1 shows sequence similarity to the protein-coding gene Acidic nuclear phosphoprotein 32 family member A (ANP32A) but does not produce a functional transcript or protein product and is not involved in any known signaling pathway or cellular function. The clinical and biological significance of ANP32AP1 is limited to its annotated status as a pseudogene; it is not considered a receptor, enzyme, or therapeutic target[1][5][3][7]. If you are seeking information about the functional ANP32A protein, which is involved in chromatin modification, apoptosis, and cell cycle regulation, please specify, as this is a distinct gene and protein with established biological functions and disease associations[2][3][7]. In summary: ANP32AP1 is a genomic pseudogene without therapeutic or biological target relevance, is not druggable, and is not involved in recognized disease processes. It should not be confused with the protein-coding ANP32A.
None applicable.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Acidic nuclear phosphoprotein 32 family member A pseudogene 1 (ANP32AP1).